Key Colony Management’s Pacira BioSciences PCRX Stock Holding History

Key Colony Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$4.76M	Sell	139,000 -82,000	-37%	-$3.21M	5.72%	4
2016 Q2	$7.45M	Sell	221,000 -79,975	-27%	-$3.93M	9.5%	4
2016 Q1	$15.9M	Sell	300,975 -100,025	-25%	-$5.85M	17.61%	3
2015 Q4	$23.8M	Buy	401,000 +44,058	+12%	+$2.49M	29.13%	1
2015 Q3	$14.7M	Buy	356,942 +121,499	+52%	+$7.44M	19.52%	2
2015 Q2	$16.7M	Buy	235,443 +17,871	+8%	+$1.41M	19.42%	2
2015 Q1	$19.3M	Buy	217,572 +9,572	+5%	+$971K	18.89%	2
2014 Q4	$18.4M	Buy	208,000 +73,400	+55%	+$6.94M	16.71%	2
2014 Q3	$13M	Buy	134,600 +34,600	+35%	+$3.37M	11.31%	4
2014 Q2	$9.19M	Buy	+100,000	New	+$7.61M	6.6%	6

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Key Colony Management's PCRX Position: Q3 2016 in Review

Key Colony Management reduced its Pacira BioSciences (PCRX) stake by 37% in Q3 2016, selling an estimated $3.21M and leaving 139,000 shares worth $4.76M. The position accounts for 5.72% of the portfolio, ranked #4.

Key Colony Management first reported a position in PCRX in Q2 2014 and has held it in 10 quarters since. The position peaked at $23.8M in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

Key Colony Management held 139,000 shares of Pacira BioSciences worth $4.76M as of Q3 2016.
Key Colony Management sold 82,000 Pacira BioSciences shares in Q3 2016, an estimated $3.21M.
Pacira BioSciences made up 5.72% of Key Colony Management's portfolio in Q3 2016, its #4 holding.
Key Colony Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 10 quarters since.
Key Colony Management's Pacira BioSciences position peaked at $23.8M in Q4 2015.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Key Colony Management's 13F filing for Q3 2016, filed 14 Nov 2016.